Icon Plc $ICLR Shares Acquired by Northwestern Mutual Wealth Management Co.

Northwestern Mutual Wealth Management Co. increased its holdings in Icon Plc (NASDAQ:ICLR) by 324.3% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,976 shares of the medical research company’s stock after buying an additional 3,039 shares during the quarter. Northwestern Mutual Wealth Management Co.’s holdings in Icon were worth $578,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the business. Artisan Partners Limited Partnership boosted its position in Icon by 67.4% during the 2nd quarter. Artisan Partners Limited Partnership now owns 7,184,870 shares of the medical research company’s stock worth $1,045,039,000 after acquiring an additional 2,893,946 shares during the period. Massachusetts Financial Services Co. MA raised its stake in shares of Icon by 21.0% during the second quarter. Massachusetts Financial Services Co. MA now owns 3,752,008 shares of the medical research company’s stock valued at $545,730,000 after purchasing an additional 650,379 shares in the last quarter. Equity Investment Corp acquired a new stake in Icon in the second quarter worth about $82,264,000. Cantillon Capital Management LLC acquired a new position in Icon during the 2nd quarter valued at about $67,663,000. Finally, First Pacific Advisors LP increased its stake in Icon by 76.3% during the 2nd quarter. First Pacific Advisors LP now owns 964,120 shares of the medical research company’s stock valued at $140,231,000 after buying an additional 417,173 shares during the period. Institutional investors own 95.61% of the company’s stock.

Icon Price Performance

ICLR stock opened at $182.10 on Tuesday. Icon Plc has a one year low of $125.10 and a one year high of $228.29. The firm has a 50-day moving average of $176.72 and a two-hundred day moving average of $165.34. The firm has a market capitalization of $14.71 billion, a PE ratio of 24.64, a P/E/G ratio of 3.40 and a beta of 1.25. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 0.31.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on ICLR. Rothschild Redb upgraded shares of Icon from a “hold” rating to a “strong-buy” rating in a report on Wednesday, September 3rd. Citigroup reaffirmed a “neutral” rating and set a $200.00 price target (down from $225.00) on shares of Icon in a research note on Thursday, August 21st. UBS Group set a $220.00 price target on Icon in a research report on Friday, October 24th. Barclays cut their price objective on Icon from $190.00 to $185.00 and set an “equal weight” rating for the company in a report on Friday, October 24th. Finally, Leerink Partners set a $220.00 target price on Icon in a report on Thursday, October 23rd. Two investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat, Icon currently has a consensus rating of “Moderate Buy” and a consensus price target of $205.00.

Icon Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.